Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by fouremmon Apr 28, 2015 10:11am
231 Views
Post# 23671284

RE:RE:RE:RE:RE:RE:RE:bloomberg article....... ouch to those whom we know....

RE:RE:RE:RE:RE:RE:RE:bloomberg article....... ouch to those whom we know....Hi JK, just a couple of thoughts on your post.  Although I can't predict how this will play out I can almost guarantee RVX won't be sold out cheap in exchange for rich contracts for existing management.  That scenario would see Eastern and NGN screwed right along with the rest of the shareholders.  No one at Eastern or NGN is interested in a management contract, they are investors just like us.  Additionally, Don M's comments in the Bloomberg article posted this morning would more support the idea that he is looking to get wealthy from the sale of his RVX shares, not from a new job.  Besides he already has a rich compensation package at RVX.

As a shareholder I for one have always been happy with both Eastern's and NGN's involvement as they have deep pockets and therefore don't make deperate moves and are aligned with us as shareholders.  They also come with there own science teams that to me have always acted as defacto third party scientific validation.
Bullboard Posts